Roth MKM Maintains Buy on Cyclacel Pharmaceuticals, Lowers Price Target to $11
Roth MKM Maintains Buy on Cyclacel Pharmaceuticals, Lowers Price Target to $11
Roth MKM 維持對Cyclacel Pharmicals的買入，將目標股價下調至11美元
Roth MKM analyst Jonathan Aschoff maintains Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a Buy and lowers the price target from $21 to $11.
羅斯MKM分析師喬納森·阿肖夫維持Cyclacel Pharmicals（納斯達克股票代碼：CYCC）的買入並將目標股價從21美元下調至11美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。